PDCD1 and cancer: In light of these observations, it can be assumed that patients with preexisting AITD, and more generally autoimmune or inflammatory diseases, might represent a subgroup of cancer patients who can benefit substantially from anti‐PD‐1/PD-L1 immunotherapies 18.